QGEN - Guardant Health: Competitors Are Trading At Cheaper Valuations
After the IPO, Guardant Health (GH) delivered 133% returns. As of May 14, 2019, it sells at 38x forward sales. Other peers are trading at cheaper valuations. The market expects additional revenue from the company’s new early detection program. It explains why the EV/Forward sales ratio is that high. Undoubtedly, this name should be followed carefully. However, market participants need to understand that as of today, the risk is not low.
Business, Solutions And Partners
Founded in 2011, Guardant Health Inc. focuses on precision oncology.
Source: Company’s Website
The company sells two biopsy